Mabpharm Limited Statistics
Want to see HK:2181 full AI Analyst Report?
Mabpharm Limited (2181) Stock Statistics & Valuation Metrics
Total Valuation
Mabpharm Limited has a market cap or net worth of HKD 2.02B. The enterprise value is HKD 2.00B.
- Market Cap
- HKD 2.02B
- Enterprise Value
- HKD 2.00B
Share Statistics
Mabpharm Limited has 4,124,080,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,124,080,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Mabpharm Limited’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 0.55%.
- Return on Equity (ROE)
- 0.35
- Return on Assets (ROA)
- 0.05
- Return on Invested Capital (ROIC)
- 0.55%
- Return on Capital Employed (ROCE)
- 0.01
- Revenue Per Employee
- 1.60M
- Profits Per Employee
- 141.25K
- Employee Count
- 394
- Asset Turnover
- 0.55
- Inventory Turnover
- 0.79
Valuation Ratios
The current PE Ratio of Mabpharm Limited is 20.51. Mabpharm Limited’s PEG ratio is 0.04.
- PE Ratio
- 20.51
- PS Ratio
- 2.27
- PB Ratio
- 8.95
- Price to FCF
- 97.29
- Price to Operating Cash Flow
- 17.42
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Mabpharm Limited had revenue of 629.37M and earned 55.65M in profits. Earnings per share was 0.01.
- Revenue
- 629.37M
- Gross Profit
- 521.55M
- Operating Income
- 4.68M
- Pretax Income
- 4.05M
- Net Income
- 55.65M
- EBITDA
- 64.46M
- Earnings Per Share (EPS)
- 0.01
Cash Flow
In the last 12 months, operating cash flow was 99.49M and capital expenditures -81.67M, giving a free cash flow of 17.82M billion.
- Operating Cash Flow
- 99.49M
- Free Cash Flow
- 17.82M
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Mabpharm Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 1.03%
- Earnings Yield
- 4.89%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- -4.81%
- 50-Day Moving Average
- 0.46
- 200-Day Moving Average
- 0.45
- Relative Strength Index (RSI)
- 57.47
- Average Volume (3m)
- 59.81K
Important Dates
Mabpharm Limited upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Mabpharm Limited as a current ratio of 0.81, with Debt / Equity ratio of 207.71%
- Current Ratio
- 0.81
- Quick Ratio
- 0.56
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- 3.38
- Interest Coverage Ratio
- 0.44
Taxes
In the past 12 months, Mabpharm Limited has paid -51.60M in taxes.
- Income Tax
- -51.60M
- Effective Tax Rate
- -12.73
Enterprise Valuation
Mabpharm Limited EV to EBITDA ratio is 20.18, with an EV/FCF ratio of 109.33.
- EV to Sales
- 2.55
- EV to EBITDA
- 20.18
- EV to Free Cash Flow
- 109.33
- EV to Operating Cash Flow
- 19.58
Balance Sheet
Mabpharm Limited has HKD 93.31M in cash and marketable securities with HKD 307.88M in debt, giving a net cash position of -HKD 214.57M billion.
- Cash & Marketable Securities
- HKD 93.31M
- Total Debt
- HKD 307.88M
- Net Cash
- -HKD 214.57M
- Net Cash Per Share
- -HKD 0.05
- Tangible Book Value Per Share
- HKD 0.01
Margins
Gross margin is 85.42%, with operating margin of 4.79%, and net profit margin of 11.09%.
- Gross Margin
- 85.42%
- Operating Margin
- 4.79%
- Pretax Margin
- 4.27%
- Net Profit Margin
- 11.09%
- EBITDA Margin
- 12.63%
- EBIT Margin
- 4.79%
Analyst Forecast
The average price target for Mabpharm Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 88.38%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 8
- AI Score
- 51

